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Abstract 
Nodules (adenomas), enlarged thyroid (goiter) and inflammation of the thyroid (thyroiditis) are the 
most important risk factors for thyroid cancer. Adenomas have the largest increase in risk. Objectives: 
to discuss two cases of adenomas goiter that became aggressive during follow-ups. Cases: Two 
patients, with an average age of 64 years, referred to Nuclear Medicine dr. M. Djamil Hospital in 
Padang for bone scintigraphy examination. Both patients had thyroid surgery and histopathology 
results were adenomas. However, after the removal surgery, the patients did not have proper follow-
ups. Both patients developed pelvic pain. Bone scintigraphy showed an increase of 
radiopharmaceutical uptake at pelvic bones and computerized tomography (CT Scan) result showed 
destruction at the pelvic bone areas. Conclusions: These cases highlight the necessity for adenoma 
thyroid patients with a risk factor for thyroid cancer to have a complete follow-up program and 
sufficient length period. 
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Abstrak 
Nodul (adenoma), pembesaran kelenjar tiroid (goiter) dan radang tiroid (tiroiditis) merupakan  faktor 
risiko terjadinya kanker tiroid. Adenoma merupakan risiko terbanyak terjadinya kanker tiroid. Tujuan: 
Untuk membahas dua kasus adenoma tiroid yang menjadi agresif dikemudian hari. Kasus: Dua pasien, 
dengan usia rata-rata 64 tahun, dirujuk ke Kedokteran Nuklir Rumah Sakit dr. M. Djamil di Padang 
untuk pemeriksaan scintigraphy tulang. Kedua pasien menjalani operasi tiroid dan hasil histopatologi 
adalah adenoma. Namun, setelah operasi pengangkatan, pasien tidak melakukan pemeriksaan 
berkala sebagaimana mestinya. Kedua pasien datang dengan keluhan nyeri panggul. Scintigraphy 
tulang menunjukkan peningkatan tangkapan radiofarmaka pada tulang-tulang di pelvis. Hasil 
pemeriksaan computerized tomography (CT Scan) menunjukkan kerusakan pada daerah tulang 
panggul. Simpulan: Perlu digaris bawahi bahwa pasien adenoma tiroid yang memiliki faktor risiko 
kanker tiroid perlu  melakukan pemeriksaan berkala sebagai tindak lanjut setelah operasi. 
Kata kunci: kanker tiroid; metastasis pada tulang; scintigraphy; tiroglobulin 
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INTRODUCTION 
Adenoma of the thyroid are typically 
discrete, solitary masses. It derived from 
follicular epithelium and be called as 
follicular adenomas. Adenoma is classified 
on the basis of degree of follicle formation 
and the colloid content of the follicles.1,2 
Follicular epithelium cell origin account for 
majority of thyroid cancer.3 Nodules 
(adenomas), enlarged thyroid (goiter) and 
inflammation of thyroid (thyroiditis) are 
the most important risk factors for thyroid 
cancer. One of five of thyroid cancer cases 
(20%) has non-cancerous of thyroid 
history.4,5 Having adenomas history that be 
started particularly at young age is a risk 
factor that can lead to be a cancer.6,7 The 
aim of this study is to discuss two cases of 
adenomas goiter that became aggressive 
during follow-ups. 
CASES 
Case Report 1 
A 66-year-old woman had a pelvic bone 
pain, when she referred to a Nuclear 
Medicine from Orthopedic clinics at dr. M. 
Djamil Hospital. She had a thyroid surgery 
9 years before, and histopathology result 
was adenomatous goiter. After the 
removal surgery, she did not do follow-ups. 
The CT scan result showed a multiple bone 
destruction with a bone metastases 
impression at left anterior superior iliac 
spine and left superior pubic ramus (Figure 
1). 
 
(a) 
(b) 
Figure 1. Bone destruction at left anterior 
superior iliac spine (a) and at left superior 
pubic ramus (b). 
 
Figure 2. Thyroid scintigraphy showed a 
thyroid remnant. 
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The thyroid scintigraphy showed a residual 
thyroid tissue (Figure 2). Bone scintigraphy 
demonstrated an increased uptake at 
vertebrae lumbar IV-V, left anterior 
superior iliac spine and left superior pubic 
ramus (Figure 3). The thyroglobulin serum 
was 2 µg/L and TSH was 1.23 µIU/mL. She 
received radioiodine (NaI-131) 80 mCi 
(2.96 x103 MBq) and post therapy scan 
show a high uptake of I-131 at pelvic 
bones.
 
Figure 3. Bone scan showed a high uptake at lumbar spine IV-V and left anterior iliac spine 
and left superior pubic ramus.
Case Report 2 
A 62-year-old woman had the right hip join 
complain. She referred to our department 
for bone scintigraphy. She had lobectomy 
five years ago with adenomatous goiter 
histopathology result. The radiology x-ray 
showed a destruction at head of right 
femur and it assumed as a metastases 
process. She did not have a proper follow-
up. The bone scintigraphy showed high 
uptakes at head of right femur and pelvic 
(ilio-pubic imminence and acetabulum) 
(Figure 4). The thyroglobulin serum was 89 
µg/L and TSH was 0.571 µIU/mL.
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Figure 4. The bone scintigraphy showed high uptakes at head of right femur and right pelvic (iliopubic 
imminence and acetabulum).
 
DISCUSSIONS 
The morphologic diagnosis of the thyroid 
neoplasms is subject to pathologist 
interpretation in specific architecture and 
cytology features. Certain anatomic 
features may suggest innocence, whereas 
other point toward cancerous potential. 
Follicular adenoma and follicular 
carcinoma cannot distinguish by cytology 
alone.8 Ultimately, morphologic diagnosis 
cannot predict the biologic behaviour 
where the prediction is confounded by a 
marked discrepancy between the 
morphologic appearance of a tumour and 
its behaviours. Occasionally, miss 
classification but on the other hand, 
thyroid carcinomas can develop from 
adenomas.4,6 
In general, benign tumours are well-
differentiated and certain well-
differentiated thyroid cancer may form 
normal-appearing follicles. Thus, 
morphologic diagnosis of a well-
differentiated thyroid tumour may 
sometimes quite difficult.6,8 Furthermore, 
the highest frequency of RAS mutation in 
follicular adenomas and carcinomas 
suggests that the two may be related 
tumor.3,9 About 48% of follicular adenomas 
have point mutations in the RAS family of 
oncogenes, which have also been 
identified in 57%, 21% of follicular thyroid 
carcinoma and papillary thyroid carcinoma 
respectively.3 Progressive changing from 
follicular adenoma to follicular carcinoma 
can be explained by firstly, RAS mutation 
and PAX8-PPARγ rearrangements.  
Secondly, mRNA profiles regulate both 
tumors mostly in common and dominant 
genes in carcinomas are further amplified.7 
These conditions raise the possibility that 
some adenomas may progress to 
carcinomas. 
The aggressiveness of particular 
morphologic type of thyroid neoplasm 
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remains unpredictable in the individual 
case. An appropriate follow-up protocol 
with benign thyroid morphologic is 
important for determining their likelihood 
of developing cancer and a follow-up study 
of each neoplasm can establish the level of 
risk. It should be reminded that the cancer 
can arise from a non-malignant cell in the 
benign tumour or the benign tumour 
contain silent or indolent malignant focus. 
In two cases above, changing behaviour of 
adenomatous goiter can arise from 
normal-appearing follicles of non-
malignant cell. 
CONCLUSIONS 
Certain well-differentiated thyroid cancer 
may form normal-appearing follicles. This 
case highlights, that follow-ups should be 
complete, detailed and sufficient length for 
patients with risk factor for thyroid cancer. 
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